Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | PDE4B | Q07343 | 6/20 | 0.36 |
| ▸ | P2RX7 | Q99572 | 5/20 | 0.35 |
| ▸ | TSHR | P16473 | 2/20 | 0.35 |
| ▸ | HTT | P42858 | 2/20 | 0.35 |
| ▸ | FPR1 | P21462 | 2/20 | 0.35 |
| ▸ | FPR2 | P25090 | 2/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | THRB | P10828 | 1/20 | 0.34 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.34 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.34 |
| ▸ | USP2 | O75604 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | ESR1 | P03372 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1075615 | 0.89 | MEN1 (0.37) | SMN1; SMN2MAPTMEN1NPC1RAB9A | |
| SCHEMBL1076320 | 0.86 | MAPT (0.35) | SMN1; SMN2MAPTMEN1NPC1RAB9A | |
| SCHEMBL1073628 | 0.86 | MEN1 (0.37) | SMN1; SMN2MAPTMEN1NPC1RAB9A | |
| SCHEMBL1073760 | 0.81 | POLB (0.36) | SMN1; SMN2TSHRHTTLMNA | |
| SCHEMBL1074015 | 0.81 | GRM1 (0.39) | PDE4BP2RX7CYP1A2 | |
| SCHEMBL1075218 | 0.80 | HSP90AA1 (0.35) | SMN1; SMN2MAPTNPC1RAB9AHTT | |
| SCHEMBL1224856 | 0.80 | GRM5 (0.36) | MAPTTSHRLMNA | |
| SCHEMBL1903762 | 0.80 | HCRTR1 (0.38) | MEN1KMT2ATSHRFPR1FPR2 | |
| SCHEMBL1073566 | 0.75 | SMN1; SMN2 (0.44) | SMN1; SMN2KMT2ATSHRHTTCYP1A2 | |
| SCHEMBL1074776 | 0.74 | NOTUM (0.36) | CYP1A2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110045101-A1 | FUNGICIDAL SUBSTITUTED AZOLES | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 2011-02-24 | — | — | US | claimed |
| EP-2274284-A2 | FUNGICIDAL SUBSTITUTED AZOLES | E. I. Du Pont de Nemours and Company (US) | 2011-01-19 | — | — | EP | claimed |
| WO-2009137538-A2 | FUNGICIDAL SUBSTITUTED AZOLES | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 2009-11-12 | — | — | WO | claimed |
| WO-2009137651-A2 | FUNGICIDAL SUBSTITUTED AZOLES | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 2009-11-12 | — | — | WO | claimed |
| US-20110045101-A1 | FUNGICIDAL SUBSTITUTED AZOLES | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 2011-02-24 | — | — | US | disclosed |
| EP-2274284-A2 | FUNGICIDAL SUBSTITUTED AZOLES | E. I. Du Pont de Nemours and Company (US) | 2011-01-19 | — | — | EP | disclosed |
| WO-2009137538-A2 | FUNGICIDAL SUBSTITUTED AZOLES | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 2009-11-12 | — | — | WO | disclosed |
| WO-2009137651-A2 | FUNGICIDAL SUBSTITUTED AZOLES | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 2009-11-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110045101-A1 | FUNGICIDAL SUBSTITUTED AZOLES | CBR3, NOX3, CBR1 | SMN1; SMN2 4003/4885MAPT 4335/4885MEN1 1078/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.